Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11850533 | 0.83 | ADRB1 (0.68) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL11841871 | 0.82 | ADRB2 (0.56) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL1461292 | 0.81 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL9767993 | 0.81 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL9768011 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL29278698 | 0.79 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL29852847 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL2250 | 0.78 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL28535211 | 0.77 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL11849771 | 0.75 | ADRB2 (0.52) | ADRA2AADRA2BADRA2CADRA1AADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108869-A1 | Active Agent Delivery Devices and Methods of Using the same | GLAS USA LLC | 2024-04-04 | — | — | US | disclosed |
| US-20240082147-A1 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. | 2024-03-14 | — | — | US | disclosed |
| US-11865286-B2 | Active agent delivery devices and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230414512-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4218718-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230216595-A1 | PHARMA-INFORMATICS SYSTEM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| EP-2427178-B1 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | LABORATORY SKIN CARE INC (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11476952-B2 | Pharma-informatics system | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20210220276-A1 | Methods of Treating Skin | LABORATORY SKIN CARE, INC. | 2021-07-22 | — | — | US | disclosed |
| EP-3827747-A1 | PHARMA-INFORMATICS SYSTEM | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20020143579-A1 | System and method for targeted interventions of physician prescription practices based on deviations from expert guidelines | COMPREHENSIVE CLINICAL DEVELOPMENT, INC. (FKA COMPREHENSIVE NEUROSCIENCE, INC.) | 2002-10-03 | — | — | US | disclosed |
| EP-0861084-B1 | IMPROVED PROCESS AND COMPOSITION FOR THERAPEUTIC CISPLATIN (CDDP) | MATRIX PHARMA (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6224883-B1 | SUPPLYING TO TUMOR, CANCER | MATRIX PHARMACEUTICAL, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6077545-A | PHOTOSENSITIVE COMPOSITION, ACID GENERATOR AND ORGANOSILICON COMPOUND | MATRIX PHARMACEUTICALS, INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0861084-A4 | IMPROVED PROCESS AND COMPOSITION FOR THERAPEUTIC CISPLATIN (CDDP) | MATRIX PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5925682-A | ANTITUMOR AGENTS | IMMUNOTECH INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0861084-A1 | IMPROVED PROCESS AND COMPOSITION FOR THERAPEUTIC CISPLATIN (CDDP) | Matrix Pharmaceutical, Inc. (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0833608-A2 | REVERSE FLUOROCARBON EMULSION COMPOSITIONS FOR DRUG DELIVERY | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997016196-A1 | IMPROVED PROCESS AND COMPOSITION FOR THERAPEUTIC CISPLATIN (CDDP) | MATRIX PHARMACEUTICAL INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1996040057-A2 | REVERSE FLUOROCARBON EMULSION COMPOSITIONS FOR DRUG DELIVERY | ALLIANCE PHARMACEUTICAL CORP. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082147-A1 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | CHERP, ORAI1, CA2 | ADRA2A 2908/4885ADRA2B 4410/4885ADRA2C 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.